Respiratory Syncytial Virus: A WAidid Consensus Document on New Preventive Options DOI Creative Commons
Matteo Riccò, Bahaa Abu-Raya, Giancarlo Icardi

и другие.

Vaccines, Год журнала: 2024, Номер 12(12), С. 1317 - 1317

Опубликована: Ноя. 25, 2024

Background/Objectives: Respiratory syncytial virus (RSV) is a leading cause of respiratory infections, particularly affecting young infants, older adults, and individuals with comorbidities. Methods: This document, developed as consensus by an international group experts affiliated the World Association Infectious Diseases Immunological Disorders (WAidid), focuses on recent advancements in RSV prevention, highlighting introduction monoclonal antibodies (mAbs) vaccines. Results: Historically, treatment options were limited to supportive care antibody palivizumab, which required multiple doses. Recent innovations have led development long-acting mAbs, such nirsevimab, provide season-long protection single dose. Nirsevimab has shown high efficacy preventing severe RSV-related lower tract infections (LRTIs) reducing hospitalizations ICU admissions. Additionally, new vaccines, RSVpreF RSVpreF3, target adults demonstrated significant LRTIs clinical trials. Maternal vaccination strategies also show promise providing passive immunity newborns, protecting them during most vulnerable early months life. document further discusses global burden RSV, its economic impact, challenges implementing these preventative different healthcare settings. Conclusions: The evidence supports integration both active (vaccines) immunization approaches effective tools mitigate public health impact RSV. combined use interventions could substantially reduce morbidity mortality across various age groups populations, emphasizing importance widespread efforts.

Язык: Английский

Respiratory syncytial virus vaccine effectiveness among US veterans, September, 2023 to March, 2024: a target trial emulation study DOI
Kristina L. Bajema, Lei Yan, Yuli Li

и другие.

The Lancet Infectious Diseases, Год журнала: 2025, Номер unknown

Опубликована: Янв. 1, 2025

Язык: Английский

Процитировано

2
Characteristics of the First Italian Older Adults Vaccinated with an Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine DOI Creative Commons
Alexander Domnich, Andrea Orsi, Piero Luigi Lai

и другие.

Medicina, Год журнала: 2025, Номер 61(1), С. 67 - 67

Опубликована: Янв. 3, 2025

Background and Objectives: Three respiratory syncytial virus (RSV) vaccines have been recently made available for older adults. Understanding the principal characteristics of first vaccine-takers can pave way a successful vaccination campaign. The objective this study was to explore sociodemographic clinical Italian users an adjuvanted RSV vaccine their attitudes towards vaccination. Materials Methods: This cross-sectional conducted in 2024 Liguria (Italy). Individuals aged ≥60 years with no contraindications RSVPreF3 OA were eligible. Following vaccination, subjects filled questionnaire, which comprised items on characteristics, trust indicator (VTI). Results: A total 453 vaccinees completed survey. Their mean age 74.9 ± 8.0 years, 50.6% males. Nine ten (89.2%) individuals had ≥1 co-morbidity, cardiovascular conditions (70.4%), diseases (27.6%) diabetes (18.5%) most common. Uptake routine high: 91.2% 98.7% received 2023/2024 season influenza ≥2 COVID-19 vaccines, respectively. common reasons current general practitioner advice (43.9%), followed by willingness be protected against (20.8%) feelings being at risk (16.6%) RSV. average VTI score 91.5%, suggesting high vaccines. More positive observed (p < 0.01) among who more doses, whose or good health feeling Conclusions: novel represented high-risk comparatively prevalence co-morbidities, uptake seasonal immunization.

Язык: Английский

Процитировано

1
Development, Current Status, and Remaining Challenges for Respiratory Syncytial Virus Vaccines DOI Creative Commons
Cleo Anastassopoulou, Snežana Medić, Stefanos Ferous

и другие.

Vaccines, Год журнала: 2025, Номер 13(2), С. 97 - 97

Опубликована: Янв. 21, 2025

Respiratory syncytial virus (RSV) causes significant morbidity and mortality, especially in young children the elderly. RSV vaccine development puzzled vaccinologists for years. Safety concerns of initial formulations, lack an absolute correlate protection, need selecting appropriate attenuation antigen–adjuvant combinations contributed to delayed production. The recent stabilization RSV-F glycoprotein prefusion (preF) conformation that constitutes primary target RSV-neutralizing antibodies was key efficient design. Two protein subunit vaccines (GSK’s Arexvy Pfizer’s Abrysvo) one mRNA (Moderna’s mRESVIA) are now available. This article aims provide a comparative overview safety efficacy novel approved prevention RSV-lower respiratory tract disease (LRTD) adults 60 years age older, with updated recommendations calling expansion vaccination all at increased risk severe disease. Abrysvo is only indicated use pregnancy prevent RSV-LRTD infants from birth 6 months age. We assessment over maximum three seasons, summarizing currently available data. conclude despite decreasing time, which should be anticipated characterized by short-term immunity, clinically meaningful placebo. Guillain–Barré syndrome post or Arexvy, prompted FDA require inclusion such warnings prescribing information these two vaccines, prioritized investigated thoroughly. Furthermore, ongoing surveillance further evaluation, particularly among immunocompromised patients, frail elderly subjects, were under- not represented pivotal clinical trials, necessary. As success story combined pediatric combination conferring protection against several illnesses dose, could help improve acceptance coverage rates older adults.

Язык: Английский

Процитировано

1
Respiratory syncytial virus vaccination in older adults and patients with chronic disorders: A position paper from the Portuguese Society of Pulmonology, the Portuguese Association of General and Family Medicine, the Portuguese Society of Cardiology, the Portuguese Society of Infectious Diseases and Clinical Microbiology, the Portuguese Society of Endocrinology, Diabetes and Metabolism, and the Portuguese Society of Internal Medicine DOI Creative Commons
Tiago M. Alfaro, Filipe Froes, Cláudia Vicente

и другие.

Pulmonology, Год журнала: 2025, Номер 31(1)

Опубликована: Янв. 27, 2025

Background Respiratory syncytial virus (RSV) is an important cause of lower respiratory tract infection, hospitalisation and death in adults.

Язык: Английский

Процитировано

1
Burden of Respiratory Syncytial Virus–Associated Hospitalizations in US Adults, October 2016 to September 2023 DOI Creative Commons
Fiona P. Havers, Michael Whitaker, Michael Melgar

и другие.

JAMA Network Open, Год журнала: 2024, Номер 7(11), С. e2444756 - e2444756

Опубликована: Ноя. 13, 2024

Importance Respiratory syncytial virus (RSV) infection can cause severe illness in adults. However, there is considerable uncertainty the burden of RSV-associated hospitalizations among adults prior to RSV vaccine introduction. Objective To describe demographic characteristics hospitalized with laboratory-confirmed and estimate annual rates numbers hospitalizations, intensive care unit (ICU) admissions, in-hospital deaths. Design, Setting, Participants This cross-sectional study used data from Hospitalization Surveillance Network (RSV-NET), a population-based surveillance platform that captures 58 counties 12 states, covering approximately 8% US population. The period spanned 7 seasons 2016-2017 through 2022-2023. Included cases RSV-NET were nonpregnant aged 18 years or older residing catchment area positive test result. Exposure Laboratory-confirmed hospitalization, defined as result within 14 days before during hospitalization. Main Outcomes Measures per 100 000 adult population, stratified by age group. After adjusting for sensitivity undertesting acute respiratory illnesses, extrapolated population hospitalizations. Clinical outcome ICU admissions Results From 2016 2017 2022 2023 seasons, 16 575 (median [IQR] age, 70 [58-81] years; 9641 females [58.2%]). Excluding 2020 2021 when COVID-19 pandemic affected circulation, hospitalization ranged 48.9 (95% CI, 33.4-91.5) 76.2 55.2-122.7) 2018. Rates lowest 49 (8.6 [95% 5.7-16.8] 13.1 11.0-16.1] 2022-2023) highest 75 (244.7 207.9-297.3] 2022-2023 411.4 292.1-695.4] 2017-2018). Annual estimates 123 84 000-230 000) 193 140 000-311 admission 24 400 700-44 800) 34 900 25 500-55 600) same seasons. Estimated deaths 4680 3570-6820) 2018 2019 8620 6220-14 090) Adults accounted 45.6% (range, 43.1%-48.8%) all 38.6% 36.7%-41.0%) 58.7% 51.9%-67.1%) Conclusions Relevance In this introduction vaccines, was associated substantial adults, occurring older. Increasing vaccination has potential reduce clinical outcomes.

Язык: Английский

Процитировано

5
RSV vaccines: an elixir for healthy ageing? DOI

Harish Nair,

Thomas Williams

The Lancet Infectious Diseases, Год журнала: 2025, Номер unknown

Опубликована: Янв. 1, 2025

Язык: Английский

Процитировано

0
Update on Vaccination Recommendations for Adults with HIV DOI

Fiona Gispen,

Kristen Marks

Current HIV/AIDS Reports, Год журнала: 2025, Номер 22(1)

Опубликована: Фев. 20, 2025

Язык: Английский

Процитировано

0
Viral community-acquired pneumonia: What’s new since COVID-19 emerged? DOI
Catia Cillóniz, Alejandro J. Videla, Laura Pulido

и другие.

Expert Review of Respiratory Medicine, Год журнала: 2025, Номер unknown

Опубликована: Март 12, 2025

Introduction All over the world, viral pneumonia has a significant impact on morbidity and mortality, especially among vulnerable populations. The most common respiratory viruses causing include influenza virus, syncytial adenoviruses rhinovirus. COVID-19 pandemic changed landscape of reshaped our understanding role in this disease. We are now more aware importance early diagnosis, co-infections, effects variants, long-term consequences post-viral pneumonia.

Язык: Английский

Процитировано

0
Patient- and Community-Level Characteristics Associated With Respiratory Syncytial Virus Vaccination DOI Creative Commons
Diya Surie, Katharine A. Yuengling, Basmah Safdar

и другие.

JAMA Network Open, Год журнала: 2025, Номер 8(4), С. e252841 - e252841

Опубликована: Апрель 1, 2025

In 2023, the first respiratory syncytial virus (RSV) vaccines were recommended for US adults 60 years or older, but few data are available about which patients most likely to receive vaccine inform future RSV outreach efforts. To assess patient- and community-level characteristics associated with receipt patient knowledge attitudes related disease vaccines. During season of use from October 1, April 30, 2024, older hospitalized RSV-negative acute illness enrolled in this cross-sectional study 26 hospitals 20 states. Sociodemographic clinical abstracted health records, structured interviews conducted Age, sex, race ethnicity, pulmonary disease, immunocompromised status, long-term care facility residence, medical insurance, social vulnerability index (SVI), educational level. The exposures identified a priori as possible factors entered into modified Poisson regression model accounting state clustering, association receipt. Knowledge summarized frequencies proportions. Among 6746 median age was 73 (IQR, 66-80) 3451 (51.2%) female. 6599 self-reported 699 (10.6%) Hispanic, 1288 (19.5%) non-Hispanic Black, 4299 (65.1%) White, 313 (4.7%) other ethnicity. There 700 RSV-vaccinated (10.4%) 6046 unvaccinated (89.6%) adults. 3219 who responded questions, 1519 (47.2%) had not heard unsure; 2525 3218 (78.5%) unsure if they eligible thought not. adjusted analyses, vaccination being 75 (adjusted risk ratio [ARR], 1.23; 95% CI, 1.10-1.38, P < .001), male (ARR, 1.15; 1.01-1.30; = .04), having 1.39; 1.16-1.67; status 1.30; 1.14-1.48; low 1.47; 1.18-1.83, .001) moderate 1.21-1.79; SVI, level consisting 4 more college 2.91; 2.14-3.96; at least some technical training 1.85; 1.35-2.53; grade 12 education General Educational Development 1.44; 1.03-2.00; .03). less among residents facilities, Medicaid coverage, uninsured patients. adults, eligibility low. Older those certain conditions have received vaccine, suggesting appropriate prioritization, sociodemographic differences uptake occurred.

Язык: Английский

Процитировано

0
Recent advances in the prevention and treatment of respiratory syncytial virus disease DOI
Alexandra Sánchez-Martínez,

Tom Moore,

T. Freitas

и другие.

Journal of General Virology, Год журнала: 2025, Номер 106(4)

Опубликована: Апрель 9, 2025

Respiratory syncytial virus (RSV) is associated with considerable healthcare burden; as such, prevention and treatment of RSV have long been considered a priority. Historic failures in vaccine development had slowed the research field. However, discovery conformational change fusion protein (F) has led to advancements The pharmaceutical landscape drastically changed recent years successful trials both vaccines second-generation mAbs leading licensing roll-out these agents several countries. preventative therapeutic measures will likely significant impact on RSV-related morbidity mortality. there are still gaps protection that immunizations offer should be addressed. Many unanswered questions about infection dynamics subsequent disease focus ongoing research. This review discusses currently licensed pharmaceuticals others recently progressed clinical trials.

Язык: Английский

Процитировано

0